Using 11C-PIB PET and 18F-MK6240 PET imaging, asymptomatic ADAD mutation carriers showed significantly greater Aβ burden across cortex and striatum compared to cognitively normal controls, while tau P

Neuropathology Score: 0.500 Price: $0.50 Alzheimer's disease in_vivo Status: extracted

What This Experiment Tests

Neuropathology experiment designed to assess clinical efficacy targeting APP, PSEN1, or PSEN2 (ADAD mutations) in in_vivo. Primary outcome: Using 11C-PIB PET and 18F-MK6240 PET imaging, asymptomatic ADAD mutation carriers showed significant

Description

11C-PIB PET evaluated Aβ deposition; 18F-MK6240 PET assessed tau aggregation; participants categorized into Group 1 and Group 2 based on 18F-MK6240 uptake patterns

TARGET GENE

APP, PSEN1, or PSEN2 (ADAD mutations)

MODEL SYSTEM

in_vivo

ESTIMATED COST

TIMELINE

0 months

PATHWAY

Aβ and tau pathology

SOURCE

pmid_39962560

PRIMARY OUTCOME

Using 11C-PIB PET and 18F-MK6240 PET imaging, asymptomatic ADAD mutation carriers showed significantly greater Aβ burden across cortex and striatum compared to cognitively normal controls, while tau PET binding did not significantly differ between groups.

Scoring Dimensions

Related Hypotheses (1)

TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification0.628

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.